S100A4 and melanoma: A neutralizing monoclonal antibody targeting S100A4, 5C3, has been shown to prevent endothelial cell migration of melanoma cells in an immunodeficient mouse xenograft model [59], thus additional research on the clinically relevant efficacy of targeting S100A4 should be explored.